文献速递MDS 与骨髓增殖性肿瘤白血病

奥马他欣美普妥酸酯治疗低甲基化药物失败后高危骨髓增生异常综合征及慢性粒单核细胞白血病的II期研究

A phase II study of omacetaxine mepesuccinate for patients with higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia after failure of hypomethylating agents.
PubMed 文献 · Am J Hematol · 2018-11-15

这项II期研究评估奥马他欣美普妥酸酯(OM)治疗低甲基化药物(HMA)失败或不耐受的骨髓增生异常综合征(MDS)或慢性粒单核细胞白血病(CMML)患者,共纳入42例,中位年龄76岁。总缓解率(ORR)为33%,二倍体细胞遗传学患者缓解率高于细胞遗传学异常患者(58% vs 23%,P=0.03)。中位总生存(OS)7.5个月,1年OS率25%;二倍体患者中位OS优于细胞遗传学异常患者(14.8 vs 6.8个月,P=0.01)。

要点

  • OM在HMA失败的MDS/CMML中ORR为33%,中位OS 7.5个月,1年OS率25%。
  • 二倍体细胞遗传学患者ORR 58% vs 细胞遗传学异常23%(P=0.03),中位OS 14.8 vs 6.8个月(P=0.01)。
  • 最常见≥3级不良事件为感染11例(26%)、发热性中性粒细胞减少4例(10%)、出血3例(7%)。

核心结论

  • OM在HMA失败的MDS或CMML患者中安全且有效,结果支持进一步开发OM用于该场景。

研究设计与样本

  • II期研究,纳入42例既往HMA失败或不耐受的MDS或CMML患者,中位年龄76岁。
  • OM给药方案为1.25 mg/m²皮下注射,每12小时一次,连续3天,4至7周为一周期。
  • 主要终点为总缓解率(ORR)和总生存(OS)。

主要发现

  • 总缓解率(ORR)为33%。
  • 二倍体细胞遗传学患者缓解率高于细胞遗传学异常患者(58% vs 23%,P=0.03)。
  • 中位OS为7.5个月,1年OS率为25%。
  • 二倍体细胞遗传学患者中位OS优于细胞遗传学异常患者(14.8 vs 6.8个月,P=0.01)。
  • 2例患者持续缓解≥2年(均为MDS、二倍体细胞遗传学且RUNX1突变)。

关键数值与推荐

  • 最常见≥3级不良事件:感染11例(26%)、发热性中性粒细胞减少4例(10%)、出血3例(7%)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The outcome of patients with myelodysplastic syndromes (MDSs) after failure of hypomethylating agents (HMAs) failure is poor with a median overall survival (OS) of only 4-6 months. Omacetaxine mepesuccinate (OM) is safe and effective in myeloid malignancies but has not been studied in MDS with HMA failure. We conducted a phase II study of OM in patients with MDS or chronic myelomonocytic leukemia (CMML) who had previously failed or been intolerant to HMAs. Patients received OM at a dose of 1.25 mg/m2 subcutaneously every 12 hours for 3 consecutive days on a 4- to 7-week schedule. The primary endpoints were the overall response rate (ORR) and OS. A total of 42 patients were enrolled with a median age of 76 years. The ORR was 33%. Patients with diploid cytogenetics were more likely to respond to OM than were those with cytogenetic abnormalities (58% vs 23%, respectively; P = .03). Overall, the median OS was 7.5 months and 1-year OS rate was 25%. Patients with diploid cytogenetics had superior OS to those with cytogenetic abnormalities (median OS 14.8 vs 6.8 months, respectively; P = .01). Two patients had ongoing response to OM of 2 years or longer (both MDS with diploid cytogenetics and RUNX1 mutation). The most common grade ≥ 3 adverse events were infections in 11 patients (26%), febrile neutropenia in 4 (10%), and hemorrhage in 3 (7%). Overall, OM was safe and active in patients with MDS or CMML who experienced HMA failure. These results support the further development of OM in this setting.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Short NJ, Jabbour E, Naqvi K, et al. A phase II study of omacetaxine mepesuccinate for patients with higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia after failure of hypomethylating agents. Am J Hematol. 2018. PMID: 30328139. doi:10.1002/ajh.25318

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。